when was ingrezza approved
SAN DIEGO, April 11, 2017 /PRNewswire/-- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved INGREZZAâ¢ (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).